Author

Alexandros Lazaris

Observed names: A. LAZARIS, A. Lazaris, A. Ya. Lazaris

Institution: MedSIR (Spain)

Observed institutions: MedSIR (Spain), University General Hospital Attikon

OpenAlex ID: A5110093301

Choices of Stent and Cerebral Protection in the Ongoing ACST-2 Trial: A Descriptive Study

2017 · D.D. de Waard, A. Halliday, et al. · European Journal of Vascular and Endovascular Surgery · 16

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study

2024 · Alfonso Cortés, Elena López-Miranda, et al. · The Breast · 7

Comparative study of the immunohistochemical expression of metalloproteinases 2, 7 and 9 between clearly invasive carcinomas and “in situ” trophoblast invasion

2010 · I. IOANNIDIS, B. DIMO, et al. · Neoplasma · 7

Abstract PO1-20-02: MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC)

2024 · Antonio Llombart-Cussac, José Manuel Pérez-García, et al. · Cancer Research · 3

258TiP A phase II trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): PRIMED

2023 · J.M. Pérez-García, M. Gion Cortes, et al. · ESMO Open · 1

Breast cancer (BC) after curative chemotherapy (CT) in non-hodgkin's lymphoma (NHL): drug resistance as the major cause of treatment failure

1999 · N. Tsavaris, Ch. Zorzos, et al. · European Journal of Cancer

Experimental diabetes caused by 5-(N, N-diethylphenylazo)-8-hydroxyquinoline

1967 · Ya. A. Lazaris, A. Ya. Lazaris · Bulletin of Experimental Biology and Medicine

Works count: 7

Citation count: 34

H-index: 3

I10-index: 1